Missed the 14th Annual Meeting of ISMPP? Read the second part of our meeting report to get up to speed!
A new study from the AllTrials team sheds light on clinical trial reporting rates by non-industry sponsors.
A new, regular series in The BMJ will highlight a different unreported clinical trial every week, with the intention of improving reporting rates.
The FDAAA 2007 requires clinical trials to make results publicly available 12 months after study completion. A new tool from TrialsTracker provides a live online report on compliance.
Missed TIPPA 2018? Read our meeting report to get up to speed!
Missed ISMPP EU 2018? Duncan Campbell provides a summary of day 2 of the meeting.
Missed ISMPP EU 2018? Read our meeting report to get up to speed!
Three steps to transparency in clinical research: a new white paper from the Collaboration for Research Integrity and Transparency
Integrity and transparency are paramount to the accuracy, accessibility and credibility of medical research. Given that clinical evidence informs market approval of medical products, missing or inaccurate clinical trial data … Continue Reading Three steps to transparency in clinical research: a new white paper from the Collaboration for Research Integrity and Transparency
The ongoing push towards increased transparency around clinical trials has seen the evolution of regulatory requirements for data reporting and sharing in Europe and the US over the past decade. … Continue Reading The evolution of regulations for improved clinical trial transparency
Over two days last week (17-18 January, 2017), around 250 delegates and exhibitors attended the 2017 European meeting of the International Society for Medical Publication Professionals (ISMPP) in London. The … Continue Reading Meeting report: Summary of Day 1 of the 2017 European #ISMPP Meeting
Despite regulatory requirements and industry commitments, analyses of clinical trial transparency rates continue to report that not all clinical trial results are published within the required timelines, or at all. … Continue Reading Company-sponsored clinical transparency rates continue to improve
It has been suggested that a sizeable number of registered clinical trials fail to report their results, and that negative or null results are especially likely to remain unpublished. To help tackle … Continue Reading TrialsTracker attempts to identify trials with potentially unreported results
At this year’s World Health Summit in Berlin, a beta version of OpenTrials, an online database containing information on clinical trials from across the world, was officially launched. The project, … Continue Reading OpenTrials launches beta version of online database
The sharing of patient-level data between research groups and pharmaceutical companies has the potential to generate enormous benefits for health. However, in an article published in the BMJ, Elizabeth Pisani … Continue Reading Shared data: accessible, useable or useful?
It is a legal requirement for those responsible for certain applicable clinical trials of FDA-regulated products to register the studies on ClinicalTrials.gov and report results within a defined timeframe, as … Continue Reading Final rule clarifies and expands results reporting requirements of the FDA Amendments Act
The push for transparency of clinical trial data has gathered momentum over recent years. The World Health Organization (WHO) has called for journal submission of trial results within one year … Continue Reading Is the timely publication of clinical trial results a reality?